There is an 80% chance of recurrence with the current standard of care
Transurethral Resection of Bladder Tumor (TURBT) is the leading first-line therapy. A costly, invasive surgical procedure, TURBT is performed in a hospital under general anesthesia, with significant complications. Moreover, in up to 80% of cases the cancer returns, and that results in multiple repeat procedures which further reduce patients’ quality of life.
Vessi’s initial target is the
$1.2 billion NMIBC market
NMIBC is defined as a cancer on the surface of the inner lining of the bladder. Physical symptoms often include problems urinating, pain and blood in the urine, or sexual dysfunction; however, it may also affect mental health and lead to a significant decrease in quality of life.
Vessi freezes the tumor; eliminates the cancer
Vessi's minimally invasive solution for NMIBC provides a new, first-line, therapeutic alternative to surgery. The company's bladder-specific cryotherapy reduces the cost and eliminates the complications associated with TURBT.
Successfully ablates unwanted tissue
Eliminates risk of dispersed cancer cells
Minimizes harm to bladder functionality
Improves quality of life
THE VESSI SYSTEM
The Vessi system consists of a standalone console and a disposable device that is inserted transurethrally into the bladder.
Patent-pending, bladder specific
Balances the ideal cooling temperature and pressure for targeted cell destruction, yet protects the bladder
Designed for the specific environment of the bladder
Intuitive “same style”
for more efficient user adoption
Two patents-pending: national phase and PCT
Founder & CEO
Seasoned medical device manager with vast cryotherapy experience; prior positions with Motus GI, Galil Medical, Given Imaging; MSc, MBA, Technion Israel institute of Technology
Years of experience in pneumatics, fine mechanics, and cryogenics; prior position in the defense industry
Hands-on experience in prototyping and manufacturing at medical device start-up companies; prior position at Stimatix GI Ltd.
(now part of B. Braun)
Prof. Gilad E. Amiel,
Chairman, Department of Urology, Rambam Health Care Campus, Israel; adjunct Associate Professor of Urology, Baylor College, Houston, Texas; former President of the American Association for Cancer Education (AACE)
Prof. Yair Lotan,
Professor of Urology, Chief of Urologic Oncology, and holder of Professorship in Urology at UT Southwestern Medical Center; Medical Director of the Urology Clinic at Parkland Health and Hospital System
Former President and CEO, Elron (NASDAQ-ELRN); former Chairman Given Imaging (NASDAQ-GIVN); chairman and board member of numerous medical device companies
1. Babjuk M. Transurethral resection of non–muscle-invasive bladder cancer. European Urology Suppl 2009 8(7):542-548.
2. Traxer O1, Pasqui F, Gattegno B, Pearle MS. Technique and complications of transurethral surgery for bladder tumours. BJU Int. 2004 Sep;94(4):492-6.
3. Kamat AM, Bağcıoğlu M, Huri E. What is new in non-muscle-invasive bladder cancer in 2016 Turk J Urol. 2017 Mar; 43(1): 9–13.
4. Schmidt S et al. Quality of life in patients with non-muscle-invasive bladder cancer: one-year results of a multicentre prospective cohort study. Urol Oncol. 2015 Jan;33(1):19.e7-19.e15. doi.